GPT and metabolic dysfunction-associated steatotic liver disease: Based on a published report [8] and our previous data [9,10,11], we believed that pemafibrate therapy may be effective for NAFLD patients refractory to SGLT2 inhibitors because these two agents have different mechanisms to improve serum ALT levels.